Vanguard Global Advisers
ALT icon

Vanguard Global Advisers’s Altimmune ALT Stock Holding History

Vanguard Global Advisers’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
75,045
+32,219
+75% +$96.2K ﹤0.01% 2448
2026
Q1 		$132K Buy
+42,826
New +$182K ﹤0.01% 2611

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's ALT Position: Q2 2026 in Review

Vanguard Global Advisers increased its Altimmune (ALT) stake by 75% in Q2 2026, buying an estimated $96.2K and bringing the position to 75,045 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Vanguard Global Advisers first reported a position in ALT in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Vanguard Global Advisers held 75,045 shares of Altimmune worth $228K as of Q2 2026.
  • Vanguard Global Advisers bought 32,219 Altimmune shares in Q2 2026, an estimated $96.2K.
  • Altimmune made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2448 holding.
  • Vanguard Global Advisers first reported a position in Altimmune in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.